AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24339028 — intervention group
Group type: EXPERIMENTAL
Intervention: Volasertib (300 mg on day 1 every 3 weeks, escalated to 350 mg in cycle 2 if tolerated)
Number of subjects: 50
Study 24341332 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (15 mg twice daily for 21 days, followed by 20 mg once daily)
Number of subjects: 439
Study 24341332 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (enoxaparin overlapping with and followed by an adjusted-dose vitamin K antagonist for 3, 6, or 12 months)
Number of subjects: 439
Study 24341332 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 439
Study 24341332 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 439
Study 24342300 — intervention group
Group type: EXPERIMENTAL
Intervention: pemetrexed (500 mg/m2 IV)
Number of subjects: 154
Study 24342300 — intervention group
Group type: COMPARATOR
Intervention: docetaxel (75 mg/m2 IV)
Number of subjects: 154
Study 24342407 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-selective endothelin receptor antagonist
Number of subjects: 0
Study 24342407 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 24343893 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir (400 mg every 12 h for 4 days) with rifapentine (900 mg once weekly for 3 weeks)
Number of subjects: 21
Study 24343893 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir (400 mg every 12 h for 4 days) with rifapentine (600 mg once daily for 10 scheduled doses)
Number of subjects: 21
Study 24343893 — intervention group
Group type: COMPARATOR
Intervention: Raltegravir alone (400 mg every 12 h for 4 days)
Number of subjects: 21
Study 24344045 — intervention group
Group type: EXPERIMENTAL
Intervention: Furazolidone
Number of subjects: 0
Study 24344220 — intervention group
Group type: EXPERIMENTAL
Intervention: LMP-CTLs as adjuvant therapy
Number of subjects: 50
Study 24345357 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantera Lux paclitaxel-coated balloon
Number of subjects: 1064
Study 24345402 — intervention group
Group type: EXPERIMENTAL
Intervention: NHDL-C (discordant)
Number of subjects: 27533
Study 24345402 — intervention group
Group type: EXPERIMENTAL
Intervention: apoB (discordant)
Number of subjects: 27533
Study 24345402 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL-P (discordant)
Number of subjects: 27533
Study 24345751 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosutinib 500 mg per day
Number of subjects: 570
Study 24345753 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Number of subjects: 43
Study 24347141 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol initiation in inpatient setting
Number of subjects: 0
Study 24347141 — intervention group
Group type: COMPARATOR
Intervention: Propranolol initiation in outpatient setting
Number of subjects: 0
Study 24347462 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-751 (200 mg/m² PO daily × 7 days every 21 days)
Number of subjects: 91
Study 24347462 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-751
Number of subjects: 91
Study 24347462 — intervention group
Group type: COMPARATOR
Intervention: Historical control group (n = 136)
Number of subjects: 91
Study 24347518 — intervention group
Group type: EXPERIMENTAL
Intervention: PAM50 Risk of Recurrence score
Number of subjects: 1478
Study 24349052 — intervention group
Group type: EXPERIMENTAL
Intervention: Ataluren 4, 4, 8 mg/kg three times per day
Number of subjects: 38
Study 24349052 — intervention group
Group type: EXPERIMENTAL
Intervention: Ataluren 10, 10, 20 mg/kg
Number of subjects: 38
Study 24349052 — intervention group
Group type: EXPERIMENTAL
Intervention: Ataluren 20, 20, 40 mg/kg
Number of subjects: 38
Study 24349052 — intervention group
Group type: EXPERIMENTAL
Intervention: Ataluren (all doses)
Number of subjects: 38
Study 24349086 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g per day of ALA
Number of subjects: 1622
Study 24349086 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1622
Study 24349334 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir 400 mg twice daily for 7 days
Number of subjects: 40
Study 24349470 — intervention group
Group type: EXPERIMENTAL
Intervention: PRS-050 at 0.1 mg/kg to 10 mg/kg by IV
Number of subjects: 26
Study 24349470 — intervention group
Group type: EXPERIMENTAL
Intervention: PRS-050 infusion
Number of subjects: 26
Study 24349470 — intervention group
Group type: EXPERIMENTAL
Intervention: PRS-050
Number of subjects: 26
Study 24350732 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual-care + Sugarsquare intervention
Number of subjects: 62
Study 24350732 — intervention group
Group type: COMPARATOR
Intervention: Usual-care
Number of subjects: 62
Study 24351073 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum CXCL-9 levels in antibody-positive women with a history of abortions
Number of subjects: 105
Study 24351073 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum CXCL-11 levels in antibody-positive women with a history of abortions
Number of subjects: 105
Study 24351073 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum CXCL-9 levels in patients with AIT without RSA
Number of subjects: 105
Study 24351073 — intervention group
Group type: COMPARATOR
Intervention: CXCL-9 and -11 levels in subjects with a history of RSA
Number of subjects: 105
Study 24351073 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple linear regression analyses for abortions
Number of subjects: 105
Study 24351336 — intervention group
Group type: EXPERIMENTAL
Intervention: lenalidomide monotherapy
Number of subjects: 1
Study 24351336 — intervention group
Group type: EXPERIMENTAL
Intervention: lenalidomide/cetuximab combination treatment
Number of subjects: 1
Study 24351518 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAID therapy
Number of subjects: 4144
Study 24351877 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher Mediterranean diet score
Number of subjects: 93122
Study 24351877 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher DASH diet score
Number of subjects: 93122
Study 24351882 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time assessment of pulmonary vein disconnection using the Achieve(®) catheter (AC) in standard position
Number of subjects: 34
Study 24351882 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time assessment of pulmonary vein disconnection using the Achieve(®) catheter (AC) after moving to a more proximal position
Number of subjects: 34
Study 24351882 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time assessment of pulmonary vein disconnection using supplemental systematic pacing manoeuvres
Number of subjects: 34
Study 24351882 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall real-time assessment of pulmonary vein disconnection
Number of subjects: 34
Study 24351885 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent AF
Number of subjects: 702
Study 24351885 — intervention group
Group type: COMPARATOR
Intervention: Paroxysmal AF
Number of subjects: 702
Study 24351969 — intervention group
Group type: EXPERIMENTAL
Intervention: sorafenib
Number of subjects: 1
Study 24352251 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg/day as maintenance therapy after cCRT
Number of subjects: 66
Study 24352795 — intervention group
Group type: EXPERIMENTAL
Intervention: MLN8237 (alisertib) ECT 50 mg BID for 7 days in 21-day cycles
Number of subjects: 58
Study 24352795 — intervention group
Group type: EXPERIMENTAL
Intervention: MLN8237 (alisertib) ECT
Number of subjects: 58
Study 24352795 — intervention group
Group type: EXPERIMENTAL
Intervention: MLN8237 (alisertib)
Number of subjects: 58
Study 24353258 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial perfusion reserve (MPR)
Number of subjects: 170
Study 24353258 — intervention group
Group type: COMPARATOR
Intervention: Exercise testing
Number of subjects: 170
Study 24353258 — intervention group
Group type: COMPARATOR
Intervention: Brain natriuretic peptide (BNP)
Number of subjects: 170
Study 24354947 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational data collection on patient characteristics, therapeutic interventions, psychosocial parameters, quality of life of caregiver and patient, caregiver burden, and health economic parameters.
Number of subjects: 300
Study 24355090 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-dose schedule (M 0-6)
Number of subjects: 974
Study 24355090 — intervention group
Group type: COMPARATOR
Intervention: Three-dose schedule (M 0-1-6)
Number of subjects: 974
Study 24355487 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole therapy
Number of subjects: 1916
Study 24355823 — intervention group
Group type: EXPERIMENTAL
Intervention: Flicker-defined form (FDF) perimetry
Number of subjects: 206
Study 24355823 — intervention group
Group type: COMPARATOR
Intervention: Standard automated perimetry (SAP)
Number of subjects: 206
Study 24355824 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric exercise (2 minutes of hand-gripping)
Number of subjects: 21
Study 24356046 — intervention group
Group type: EXPERIMENTAL
Intervention: INCRAFT® Stent-Graft System
Number of subjects: 60
Study 24356623 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib 100 mg orally daily (maximally tolerated dose)
Number of subjects: 32
Study 24356623 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib added to infusional 5-FU 225 mg/M2/day, bevacizumab 5 mg/kg, and radiation 50.4 Gy in 28 fractions
Number of subjects: 32
Study 24356623 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib added to infusional 5-FU, bevacizumab and radiation
Number of subjects: 32
Study 24356628 — intervention group
Group type: EXPERIMENTAL
Intervention: High p-AKT expression group
Number of subjects: 262
Study 24356628 — intervention group
Group type: EXPERIMENTAL
Intervention: High p-AKT expression group with concurrent Epstein-Barr virus positivity
Number of subjects: 262
Study 24356628 — intervention group
Group type: COMPARATOR
Intervention: Low p-AKT expression group
Number of subjects: 262
Study 24356787 — intervention group
Group type: EXPERIMENTAL
Intervention: PHiD-CV booster dose co-administered with DTPa booster dose
Number of subjects: 104
Study 24356787 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-dose catch-up with PHiD-CV (first dose co-administered with DTPa booster dose)
Number of subjects: 104
Study 24358067 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg twice daily
Number of subjects: 4484
Study 24358067 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac SR 75 mg twice daily plus omeprazole 20 mg daily
Number of subjects: 4484
Study 24358863 — intervention group
Group type: EXPERIMENTAL
Intervention: Low pain threshold group
Number of subjects: 40
Study 24359231 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutch version of the Western Ontario Rotator Cuff Index (WORC)
Number of subjects: 57
Study 24359231 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutch WORC
Number of subjects: 57
Study 24359243 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Number of subjects: 0
Study 24359635 — intervention group
Group type: EXPERIMENTAL
Intervention: New antipsychotic monotherapy treatment initiated within 2 weeks prior to enrollment
Number of subjects: 568
Study 24359635 — intervention group
Group type: EXPERIMENTAL
Intervention: New antipsychotic monotherapy treatment
Number of subjects: 568
Study 24359972 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (max CGM glucose value ≥ 11 mmol/l)
Number of subjects: 38
Study 24359972 — intervention group
Group type: COMPARATOR
Intervention: Group 1 (max CGM glucose value < 11 mmol/l)
Number of subjects: 38
Study 24360325 — intervention group
Group type: EXPERIMENTAL
Intervention: CD49d-expressing neutrophils
Number of subjects: 0
Study 24360325 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 24360599 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine treatment (20-40 mg/day)
Number of subjects: 16
Study 24360599 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine nonresponders
Number of subjects: 16
Study 24360599 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine treatment
Number of subjects: 16
Study 24360789 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment, mean final dose 0.6 (0.25) mg
Number of subjects: 39
Study 24360789 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment
Number of subjects: 39
Study 24360866 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 24360992 — intervention group
Group type: EXPERIMENTAL
Intervention: Mildly elevated ALT
Number of subjects: 91
Study 24360992 — intervention group
Group type: COMPARATOR
Intervention: Normal ALT
Number of subjects: 91
Study 24360992 — intervention group
Group type: COMPARATOR
Intervention: Elevated ALT
Number of subjects: 91
Study 24360992 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall biopsy analysis
Number of subjects: 91
Study 24361681 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted darunavir monotherapy (MtDRV/rtv)
Number of subjects: 144
Study 24361681 — intervention group
Group type: COMPARATOR
Intervention: Virological failure episodes
Number of subjects: 144
Study 24361681 — intervention group
Group type: COMPARATOR
Intervention: Adherence less than 95%
Number of subjects: 144
Study 24361681 — intervention group
Group type: COMPARATOR
Intervention: Basal proviral DNA levels more than 2 log10 copies/10 PBMCs
Number of subjects: 144
Study 24361682 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir/emtricitabine
Number of subjects: 33
Study 24361682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 24362550 — intervention group
Group type: EXPERIMENTAL
Intervention: Triapine (105 mg/m²/day) followed by fludarabine (30 mg/m²/day) daily for 5 consecutive days
Number of subjects: 37
Study 24363672 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemomechanical caries removal with Papacarie gel
Number of subjects: 20
Study 24363672 — intervention group
Group type: COMPARATOR
Intervention: Removal of carious dentin with low-speed bur (Control Group)
Number of subjects: 20
Study 24363760 — intervention group
Group type: EXPERIMENTAL
Intervention: TPN (Total Parenteral Nutrition)
Number of subjects: 51
Study 24363760 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral arginine, peripheral TPN
Number of subjects: 51
Study 24363760 — intervention group
Group type: EXPERIMENTAL
Intervention: TPN preoperatively
Number of subjects: 51
Study 24363760 — intervention group
Group type: COMPARATOR
Intervention: Without nutrition (control group)
Number of subjects: 51
Study 24363954 — intervention group
Group type: EXPERIMENTAL
Intervention: real-rTMS
Number of subjects: 11
Study 24363954 — intervention group
Group type: COMPARATOR
Intervention: sham-rTMS
Number of subjects: 11
Study 24363955 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful Group (SG)
Number of subjects: 61
Study 24363955 — intervention group
Group type: COMPARATOR
Intervention: Less Successful Group (LSG)
Number of subjects: 61
Study 24365086 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard diet (33% fat, 52% carbohydrate, 15% protein) for 7 days followed by a test meal (40% fat, 40% carbohydrate, 20% protein) on Day 8.
Number of subjects: 31
Study 24365086 — intervention group
Group type: EXPERIMENTAL
Intervention: Race, SI, VAT and apolipoproteins in random effects models (REM).
Number of subjects: 31
Study 24365862 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma male patients
Number of subjects: 2291
Study 24365862 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma female patients
Number of subjects: 2291
Study 24365862 — intervention group
Group type: EXPERIMENTAL
Intervention: Nontrauma male patients
Number of subjects: 2291
Study 24365862 — intervention group
Group type: EXPERIMENTAL
Intervention: Nontrauma female patients
Number of subjects: 2291
Study 24365862 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma patients
Number of subjects: 2291
Study 24365862 — intervention group
Group type: EXPERIMENTAL
Intervention: Men (general)
Number of subjects: 2291
Study 24366423 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythritol 36 g/day as an orange-flavored beverage for 4 weeks
Number of subjects: 24
Study 24366583 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (4 mg) twice daily until birth
Number of subjects: 12
Study 24366929 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain management
Number of subjects: 3106
Study 24366929 — intervention group
Group type: EXPERIMENTAL
Intervention: Inadequate pain management
Number of subjects: 3106
Study 24366929 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower baseline pain level
Number of subjects: 3106
Study 24366929 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 3106
Study 24366929 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor health status
Number of subjects: 3106
Study 24367599 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir, tenofovir disoproxil fumarate, and emtricitabine
Number of subjects: 39
Study 24367942 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma-Focused Cognitive Behavioral Therapy (TF-CBT)
Number of subjects: 30
Study 24368064 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-weekly gemcitabine (starting dose 15 mg/m², escalated to 20, 25, and 30 mg/m²) and cisplatin (CDDP 20 mg/m²/day over 4 days every 21 days) with concomitant radiation therapy (63 Gy in 1.8 fractions)
Number of subjects: 14
Study 24368064 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-weekly gemcitabine (30 mg/m²)
Number of subjects: 14
Study 24368985 — intervention group
Group type: EXPERIMENTAL
Intervention: SILS cholecystectomy
Number of subjects: 100
Study 24368985 — intervention group
Group type: COMPARATOR
Intervention: TPCL cholecystectomy
Number of subjects: 100
Study 24369044 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong SOC (score 0-1)
Number of subjects: 250
Study 24369044 — intervention group
Group type: COMPARATOR
Intervention: Weak SOC (score 2-6)
Number of subjects: 250
Study 24369057 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic device (Nosten®) for continuous control of cuff pressure (Pcuff) for 24 hours
Number of subjects: 64
Study 24369057 — intervention group
Group type: COMPARATOR
Intervention: Routine care of cuff pressure using a manometer for 24 hours
Number of subjects: 64
Study 24369057 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic device (Nosten®) for continuous control of cuff pressure (Pcuff)
Number of subjects: 64
Study 24369057 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous control of Pcuff
Number of subjects: 64
Study 24369094 — intervention group
Group type: EXPERIMENTAL
Intervention: Belinostat (PXD101) administered intravenously at a dose of 1000 mg/m² daily on days 1-5 of a 21-day cycle until progression or unacceptable toxicity.
Number of subjects: 12
Study 24369412 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg adalimumab every other week
Number of subjects: 41
Study 24369764 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide twice daily (BID)
Number of subjects: 2388
Study 24369764 — intervention group
Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 2388
Study 24370210 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine and sorafenib (MTD)
Number of subjects: 41
Study 24371246 — intervention group
Group type: EXPERIMENTAL
Intervention: Expanded Quantitative Urine Culture (EQUC) protocol
Number of subjects: 65
Study 24371246 — intervention group
Group type: COMPARATOR
Intervention: Standard urine culture protocol
Number of subjects: 65
Study 24372730 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage partial low-dose rate brachytherapy
Number of subjects: 616
Study 24372730 — intervention group
Group type: COMPARATOR
Intervention: Initial low-dose rate brachytherapy
Number of subjects: 616
Study 24373120 — intervention group
Group type: EXPERIMENTAL
Intervention: Caspofungin + voriconazole
Number of subjects: 84
Study 24373120 — intervention group
Group type: EXPERIMENTAL
Intervention: Caspofungin + liposomal amphotericin B (L-AmB)
Number of subjects: 84
Study 24373120 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (combo)
Number of subjects: 84
Study 24373343 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy (estrogen-alone and estrogen plus progestin)
Number of subjects: 720
Study 24373573 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective surgeries (various types)
Number of subjects: 2397
Study 24373573 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Douleur Neuropathique 4 Questions (DN4)
Number of subjects: 2397
Study 24373573 — intervention group
Group type: EXPERIMENTAL
Intervention: Time since surgery
Number of subjects: 2397
Study 24373573 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age and low anxiety score
Number of subjects: 2397
Study 24373573 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent negative event, low preoperative quality of life, previous history of peripheral neuropathy
Number of subjects: 2397
Study 24373573 — intervention group
Group type: COMPARATOR
Intervention: Type of anesthesia
Number of subjects: 2397
Study 24373580 — intervention group
Group type: EXPERIMENTAL
Intervention: High plasma YKL-40 (concentration higher than the 75th percentile for age-matched healthy subjects)
Number of subjects: 493
Study 24373580 — intervention group
Group type: COMPARATOR
Intervention: Normal plasma YKL-40 levels
Number of subjects: 493
Study 24373580 — intervention group
Group type: EXPERIMENTAL
Intervention: YKL-40 levels
Number of subjects: 493
Study 24373580 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 493
Study 24373580 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe COPD
Number of subjects: 493
Study 24373580 — intervention group
Group type: EXPERIMENTAL
Intervention: Very severe COPD
Number of subjects: 493
Study 24373580 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophil granulocyte count
Number of subjects: 493
Study 24373580 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking history of > 40 years
Number of subjects: 493
Study 24373638 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency radiotherapy (RT) started within 12 hours after onset of neurological symptoms.
Number of subjects: 10
Study 24374423 — intervention group
Group type: EXPERIMENTAL
Intervention: Medically treated
Number of subjects: 500
Study 24374423 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgically treated
Number of subjects: 500
Study 24374423 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (banding)
Number of subjects: 500